[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 25 September 2020]
We are inviting expressions of interest (EoI) for commercializing “A Synbiotic Compsotion for Immunity” technology. The innovation is developed by Professor Siew Chien Ng, Professor of the Department of Medicine and Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 20/MED/975).
The Technology
This invention defines a symbiotic composition for the prevention and/or treatment of infection including respiratory infections including Coronavirus disease-2019 (COVID-19), influenza, respiratory syncytial virus, and to improve immunity. This symbiotic composition is derived from big data and advanced bioinformatics. The practical use of the invention include development and manufacturing of commercial food products or health supplements for example in the form of sachet, tablet, capsule, which can be taken alone, added to food or beverages as well as made into food product.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
